Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Descriptor ID |
D002289
|
MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 3 | 0 | 3 |
2006 | 1 | 0 | 1 |
2007 | 4 | 0 | 4 |
2009 | 2 | 0 | 2 |
2010 | 5 | 0 | 5 |
2011 | 1 | 0 | 1 |
2012 | 6 | 0 | 6 |
2013 | 4 | 0 | 4 |
2014 | 6 | 1 | 7 |
2015 | 2 | 1 | 3 |
2016 | 17 | 1 | 18 |
2017 | 169 | 11 | 180 |
2018 | 169 | 15 | 184 |
2019 | 81 | 5 | 86 |
2020 | 5 | 0 | 5 |
2021 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells. Cancer Genomics Proteomics. 2021 Sep-Oct; 18(5):661-673.
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct; 99:108012.
-
Alectinib continuation during COVID 19 'antiviral' treatment: Risk or benefit? J Oncol Pharm Pract. 2021 Jul; 27(5):1251-1254.
-
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia. Eur Rev Med Pharmacol Sci. 2021 05; 25(10):3868-3878.
-
Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. Ann Surg. 2021 05 01; 273(5):850-857.
-
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021 08; 17(8):e1235-e1245.
-
Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic. Expert Rev Anticancer Ther. 2021 06; 21(6):569-572.
-
Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opin Drug Saf. 2021 Jun; 20(6):651-667.
-
Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
-
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy. 2021 04; 13(6):509-525.